With decreased step length and dramatic exacerbation of muscle pathology in mdx-ApoE mice as early as 4–7 months of age, we suggest that our model exhibits superiority to the commonly used mdx/utrn DKO model of MD in key areas. This evidence concerns the gene APOE and Menkes disease.